Latest Marketable Securities News

BPH Global has transitioned from development to early commercial sales in its Indonesian seaweed operations, securing key offtake agreements and advancing multiple R&D projects. The company also raised $609,000 in fresh capital, positioning itself for growth in sustainable biotech markets.

ECP Emerging Growth Limited reports steady financial health for its convertible notes, confirming a stable loan-to-value ratio and full compliance with regulatory requirements for Q2 2025.

Global Masters Fund Limited has released its quarterly update confirming stable convertible note conversions and a low loan-to-value ratio, underscoring its solid financial footing as of June 2025.

Flagship Investments Limited has reported steady financial health in its latest quarterly filing, confirming a stable loan-to-value ratio and full compliance with convertible note obligations for Q2 2025.

Pentanet Limited has secured a $2 million finance facility to fund the final payment for its 5G spectrum licence, reinforcing its growth strategy in telecommunications and cloud gaming.

GenusPlus Group has landed a $130 million contract to upgrade NBN’s Fibre to the Node network across Western Australia, targeting 22,000 properties over the next 3.5 years.

EBR Systems has won FDA approval for its pioneering leadless WiSE CRT System, setting the stage for a phased US commercial rollout. The company also secured key Medicare reimbursement pathways and expanded manufacturing capacity, though financial sustainability remains a concern.

AVITA Medical reported a strong first quarter with revenues up 67% to $18.5 million, driven by expanded commercial sales and new product introductions. Despite a narrower net loss, the company faces ongoing challenges from revenue covenants and macroeconomic pressures.

Novo Resources reported a reduced net loss of CAD 1.625 million in Q1 2025, progressing exploration with a new aircore drilling program in Western Australia while facing liquidity challenges that cast doubt on its near-term financial sustainability.

Contact Energy has received clearance from the New Zealand Commerce Commission to proceed with its acquisition of Manawa Energy, marking a pivotal step in the country’s energy transition.

Argenica Therapeutics has completed patient dosing in its Phase 2 trial of ARG-007 for acute ischaemic stroke, with topline data expected in Q3 2025. The company also plans to submit its Investigational New Drug application and Fast Track request to the FDA imminently.

Contact Energy reported a 12% rise in EBITDAF to $404 million for 1H25, driven by new geothermal assets and strategic contracts, while net profit fell 7% due to market volatility and acquisition costs.